Document is current
Any future updates will be listed below
-
Authors
Nychas, Emmanouil
Marfil-Sánchez, Andrea
Chen, Xiuqiang
Mirhakkak, Mohammad
Li, Huating
Jia, Weiping
Xu, Aimin
Nielsen, Henrik Bjørn
Nieuwdorp, Max
Loomba, Rohit
Ni, Yueqiong
Panagiotou, Gianni
- License Information
-
More Information
Article History
Received: 3 November 2024
Accepted: 26 November 2024
First Online: 14 January 2025
Declarations
:
: For the cohorts that are not associated with a published study, ethics approvals were obtained by the Shanghai Jiao Tong University Affiliated Sixth People’s Hospital (approval no: 2015-65-(1)) and the University of Hong Kong / Hospital Authority Hong Kong West Cluster (approval no: UW 20-700) following the principles of the Declaration of Helsinki.
: Written informed consent was obtained from all participants from all the cohorts that are not associated with a published study.
: M.N. is founder and scientific advisor of Caelus Health that is commercializing A. soehngenii for metabolic disease treatment. R.L. serves as a consultant to Aardvark Therapeutics, Altimmune, Arrowhead Pharmaceuticals, AstraZeneca, Cascade Pharmaceuticals, Eli Lilly, Gilead, Glympse bio, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Lipidio, Madrigal, Neurobo, Novo Nordisk, Merck, Pfizer, Sagimet, 89 bio, Takeda, Terns Pharmaceuticals and Viking Therapeutics. In addition, his institution received research grants from Arrowhead Pharmaceuticals, Astrazeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Gilead, Intercept, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, Novo Nordisk, Pfizer, Sonic Incytes and Terns Pharmaceuticals. Co-founder of LipoNexus Inc. All other authors declare that they have no competing interests.
